Natera, Inc. NTRA
319.44 USD +8.77 (+2.82%)
Nov 9, 2026, 2:07 PM EST
308.03 Day range 324.77
181.00 52-week range 437.41
- YTD
- +39.44%
- 1 year
- +60.06%
News
benzinga.com Baird Maintains Outperform on Natera, Lowers Price Target to $403 Baird analyst Catherine Ramsey maintains Natera (NASDAQ:NTRA) with a Outperform and lowers the price target from $458 to $403.
seekingalpha.com Natera, Inc. (NTRA) Q3 2026 Earnings Call Transcript Natera, Inc. ( NTRA ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of…
benzinga.com JP Morgan Maintains Overweight on Natera, Lowers Price Target to $405 JP Morgan analyst Casey Woodring maintains Natera (NASDAQ:NTRA) with a Overweight and lowers the price target from $460 to $405.
benzinga.com Natera Stock Plummets After Mixed Q3 Financials Natera shares are plunging Friday after mixed Q3 results, as a wider-than-expected loss offset revenue and guidance that topped estimates.
benzinga.com If You Invested $100 In Natera Stock 10 Years Ago, You Would Have This Much Today Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.7% on an annualized basis producing an average annual return of 40.73%. Currently, Natera has a market capitalization of…
benzinga.com Evercore ISI Group Maintains Outperform on Natera, Lowers Price Target to $400 Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and lowers the price target from $468 to $400.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.
marketbeat.com What Natera (NTRA) Said on Its Q3 Earnings Call Natera NASDAQ: NTRA raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in…
benzinga.com Natera Q3 2026 Earnings Call Transcript Natera (NASDAQ:NTRA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…
benzinga.com Natera Q3 EPS $(0.42) Misses $(0.29) Estimate, Sales $793.981M Beat $704.901M Estimate Natera (NASDAQ:NTRA) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.29) by 44.83 percent. This is a 34.38 percent increase over losses of $(0.64)…- benzinga.com Natera Raises FY2026 Sales Guidance from $2.850B-$2.910B to $3.005B-$3.035B vs $2.907B Est Natera (NASDAQ:NTRA) raises FY2026 sales outlook from $2.850 billion-$2.910 billion to $3.005 billion-$3.035 billion vs $2.907 billion estimate.
benzinga.com Toyota, ConocoPhillips On Deck Thursday As Auto Demand, Oil Prices Face Test Toyota Motor headlines Thursday’s reports, with investors weighing the automaker’s earnings outlook against a stock still well below its 52-week high. ConocoPhillips, Sony Group, Parker Hannifin and…
businesswire.com Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced three peer-reviewed publications in npj Precision Oncology, JAMA…
defenseworld.net Aware Super Pty Ltd as trustee of Aware Super Buys 16,018 Shares of Natera, Inc. $NTRA Aware Super Pty Ltd as trustee of Aware Super bought a new stake in Natera, Inc. (NASDAQ: NTRA) during the undefined quarter, according to the company in its most recent Form 13F filing with the…
businesswire.com Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has…
benzinga.com Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
benzinga.com Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet The Stock Whisper Index is a market indicator highlighting stocks that are attracting heightened interest from traders and investors over the last trading week.
benzinga.com Natera, Shake Shack, eBay And More On CNBC’s ‘Final Trades’ CNBC Final Trades: Sechan picked eBay, Simpson Natera, Thomas COWZ ETF and Brown Shake Shack; all four gained Thursday.
benzinga.com BTIG Maintains Buy on Natera, Raises Price Target to $430 BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $320 to $430.
benzinga.com Natera Highlights New Signatera Genome Assay Data At ESMO 2026, With ctDNA Dynamics Predictive Of Survival Outcomes In Bladder Cancer Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO OpenNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free…
benzinga.com $100 Invested In Natera 5 Years Ago Would Be Worth This Much Today Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 17.81% on an annualized basis producing an average annual return of 28.94%. Currently, Natera has a market capitalization of…- benzinga.com Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $500 Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $375 to $500.
- benzinga.com Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $435 Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $355 to $435.
- benzinga.com TD Cowen Maintains Buy on Natera, Raises Price Target to $480 TD Cowen analyst Dan Brennan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $340 to $480.
- benzinga.com Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based…
benzinga.com Natera Reports Q2 2026 Results: Full Earnings Call Transcript On Thursday, Natera (NASDAQ:NTRA) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call…- benzinga.com Natera Receives FDA's Breakthrough Device Designation For Its Multi-Cancer Early Detection Assay Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device…
- benzinga.com Barclays Maintains Overweight on Natera, Raises Price Target to $475 Barclays analyst Luke Sergott maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $340 to $475.
- benzinga.com Citigroup Maintains Buy on Natera, Raises Price Target to $480 Citigroup analyst Albert Hu maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $365 to $480.
benzinga.com $1000 Invested In Natera 10 Years Ago Would Be Worth This Much Today Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 29.68% on an annualized basis producing an average annual return of 43.44%. Currently, Natera has a market capitalization of…- benzinga.com Alliance Foundation Trials And Natera Launch AFT-70 NAVIGATE, Randomized Phase III Trial Evaluating MRD-Guided Treatment Strategy For Patients With Intermediate And High-Risk ER-Positive/HER2-Negative Early Breast Cancer Trial will use Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s investigational oral SERD, aiming to spare…
- benzinga.com Guggenheim Maintains Buy on Natera, Raises Price Target to $475 Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $360 to $475.
benzinga.com Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You A look at the stocks that are owned by Cathie Wood's Ark Invest and Donald Trump.
benzinga.com $1000 Invested In Natera 5 Years Ago Would Be Worth This Much Today Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 17.64% on an annualized basis producing an average annual return of 29.65%. Currently, Natera has a market capitalization of…
benzinga.com Natera, UnitedHealth Group And A Tech Stock On CNBC’s ‘Final Trades’ CNBC’s Final Trades: Rob Sechan picks Hewlett Packard, Kevin Simpson favors Natera, and Stephen Weiss recommends UnitedHealth.
benzinga.com RBC Capital Maintains Outperform on Natera, Raises Price Target to $460 RBC Capital analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Outperform and raises the price target from $350 to $460.
benzinga.com Uber, Micron, Datadog And A Health Care Stock: CNBC’s ‘Final Trades’ CNBC’s Final Trades featured Uber, Micron, Natera and Datadog, with analysts citing bullish views and all four stocks posting gains.- benzinga.com Japan’s Pharmaceuticals And Medical Devices Agency Issues Regulatory Approval To Natera's Signatera Test This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) treatment decisions in patients with MIBC. Natera expects to commercially launch Signatera for MIBC in…
benzinga.com UBS Maintains Buy on Natera, Raises Price Target to $435 UBS analyst Doug Schenkel maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $290 to $435.- benzinga.com Rothschild & Co Initiates Coverage On Natera with Buy Rating, Announces Price Target of $385 Rothschild & Co analyst Jamie Clark initiates coverage on Natera (NASDAQ:NTRA) with a Buy rating and announces Price Target of $385.
- benzinga.com Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.54% on an annualized basis producing an average annual return of 40.97%. Currently, Natera has a market capitalization of…
benzinga.com Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 results and raised FY26 sales guidance. Other big gains include DOCS, QNST, TEAM, CRSR, OABI, PUBM, TWLO,…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings…
benzinga.com Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.- benzinga.com Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and plans to initiate the trial in late 2026.Under the agreement, Natera’s Prospera test will serve as…
benzinga.com Why Is Natera Stock Gaining Tuesday? Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the full NTRA stock analysis.
benzinga.com Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets under management climbed to $476 million.- benzinga.com 'AI Investor Coatue Joins Data Center Frenzy With New Venture to Buy Land' - Wall Street Journal https://www.wsj.com/tech/ai/ai-investor-coatue-joins-data-center-frenzy-with-new-venture-to-buy-land-9f4c374f?reflink=desktopwebshare_permalink
benzinga.com Allogene Therapeutics Stock Hits 52-Week High - Here's Why Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.